Curia, a contract research, development and manufacturing organisation and Carterra, a company specialising in label-free high throughput antibody and small molecule drug discovery, has partnered to host a high-throughput biologics symposium scheduled for May 31 at the Residence Inn at Marriott in Seattle, Washington.
The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the US and Canada. The symposium will bring together all levels of scientific leadership from the biotech and pharma communities.
"We are thrilled to be partnering with Carterra to organise this antibody discovery symposium, bringing the Pacific Northwest biotech community together and sharing the latest advances in antibody discovery," said Steve Lavezoli, Vice President of Biologics at Curia. "We are also looking forward to sharing our optimal, high-quality and accelerated antibody discovery workflows to first-to-human antibody discovery, development and clinical manufacturing. Antibodies discovered and/or engineered with Curia’s platform technology are in the clinic and we have over 230 successful antibody discovery campaigns performed for the biotech community."
Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.
The symposium will highlight Curia’s technology platform and integrated services with a focus on the development of enhanced mouse systems for antibody generation and high-throughput single B cell screening. The combination of next generation sequencing (NGS) and rapid recombinant production of milligram to gram quantities of purified monoclonal antibody (mAb) significantly accelerates identification of development candidate leads.
